Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1974 1
1982 1
1983 1
1987 5
1989 1
1990 2
1991 1
1994 3
1996 2
1997 5
1998 1
1999 1
2000 1
2001 4
2002 6
2003 9
2004 4
2005 11
2006 7
2007 9
2008 14
2009 8
2010 23
2011 9
2012 3
2013 5
2014 8
2015 8
2016 14
2017 6
2018 10
2019 15
2020 16
2021 19
2022 18
2023 11

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Results by year

Filters applied: . Clear all
Page 1
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, Harrison CN, McMullin MF, Vannucchi AM, Ewing J, O'Connell CL, Kiladjian JJ, Mead AJ, Winton EF, Leibowitz DS, De Stefano V, Arcasoy MO, Kessler CM, Catchatourian R, Rondelli D, Silver RT, Bacigalupo A, Nagler A, Kremyanskaya M, Levine MF, Arango Ossa JE, McGovern E, Sandy L, Salama ME, Najfeld V, Tripodi J, Farnoud N, Penson AV, Weinberg RS, Price L, Goldberg JD, Barbui T, Marchioli R, Tognoni G, Rampal RK, Mesa RA, Dueck AC, Hoffman R. Mascarenhas J, et al. Among authors: yacoub a. Blood. 2022 May 12;139(19):2931-2941. doi: 10.1182/blood.2021012743. Blood. 2022. PMID: 35007321 Free PMC article. Clinical Trial.
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.
Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV. Lonial S, et al. Among authors: yacoub am. J Clin Oncol. 2020 Apr 10;38(11):1126-1137. doi: 10.1200/JCO.19.01740. Epub 2019 Oct 25. J Clin Oncol. 2020. PMID: 31652094 Free PMC article. Clinical Trial.
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R. Yacoub A, et al. Blood. 2019 Oct 31;134(18):1498-1509. doi: 10.1182/blood.2019000428. Blood. 2019. PMID: 31515250 Free PMC article. Clinical Trial.
Targeting QKI-7 in vivo restores endothelial cell function in diabetes.
Yang C, Eleftheriadou M, Kelaini S, Morrison T, González MV, Caines R, Edwards N, Yacoub A, Edgar K, Moez A, Ivetic A, Zampetaki A, Zeng L, Wilkinson FL, Lois N, Stitt AW, Grieve DJ, Margariti A. Yang C, et al. Among authors: yacoub a. Nat Commun. 2020 Jul 30;11(1):3812. doi: 10.1038/s41467-020-17468-y. Nat Commun. 2020. PMID: 32732889 Free PMC article.
Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.
Mazza GL, Mead-Harvey C, Mascarenhas J, Yacoub A, Kosiorek HE, Hoffman R, Dueck AC, Mesa RA; Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 trial teams. Mazza GL, et al. Among authors: yacoub a. Lancet Haematol. 2022 Jan;9(1):e38-e48. doi: 10.1016/S2352-3026(21)00343-4. Lancet Haematol. 2022. PMID: 34971581 Free PMC article. Clinical Trial.
Targeting the PI3K pathway in myeloproliferative neoplasms.
Gerds AT, Bartalucci N, Assad A, Yacoub A. Gerds AT, et al. Among authors: yacoub a. Expert Rev Anticancer Ther. 2022 Aug;22(8):835-843. doi: 10.1080/14737140.2022.2093192. Epub 2022 Jun 29. Expert Rev Anticancer Ther. 2022. PMID: 35763287 Review.
MDA-7/IL-24 as a cancer therapeutic: from bench to bedside.
Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, Sarkar D, Gupta P, Emdad L, Lebedeva IV, Sauane M, Su ZZ, Rahmani M, Broaddus WC, Young HF, Lesniak M, Grant S, Curiel DT, Fisher PB. Dent P, et al. Among authors: yacoub a. Anticancer Drugs. 2010 Sep;21(8):725-31. doi: 10.1097/CAD.0b013e32833cfbe1. Anticancer Drugs. 2010. PMID: 20613485 Free PMC article. Review.
The development of MDA-7/IL-24 as a cancer therapeutic.
Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, Sarkar D, Wang XY, Gupta P, Emdad L, Lebedeva IV, Sauane M, Su ZZ, Rahmani M, Broaddus WC, Young HF, Lesniak MS, Grant S, Curiel DT, Fisher PB. Dent P, et al. Among authors: yacoub a. Pharmacol Ther. 2010 Nov;128(2):375-84. doi: 10.1016/j.pharmthera.2010.08.001. Epub 2010 Aug 21. Pharmacol Ther. 2010. PMID: 20732354 Free PMC article. Review.
240 results